Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

Abstract Background In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) bu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2021-02, Vol.76 (3), p.738-742
Main Authors: Rial-Crestelo, David, de Miguel, Rosa, Montejano, Rocío, Dominguez-Dominguez, Lourdes, Aranguren-Rivas, Paula, Esteban-Cantos, Andrés, Bisbal, Otilia, Santacreu-Guerrero, Mireia, Garcia-Alvarez, Mónica, Alejos, Belén, Hernando, Asunción, Bermejo-Plaza, Laura, Cadiñanos, Julen, Mayoral, Mario, Castro, Juan Miguel, Moreno, Victoria, Martin-Carbonero, Luz, Delgado, Rafael, Rubio, Rafael, Pulido, Federico, Arribas, José Ramón
Format: Article
Language:English
Subjects:
Adult
Anti-HIV Agents - therapeutic use
Drug Therapy, Combination
Heterocyclic Compounds, 3-Ring
HIV Infections - drug therapy
HIV-1 - genetics
Humans
Lamivudine - therapeutic use
Oxazines
Pilot Projects
Piperazines - therapeutic use
Pyridones
Retrospective Studies
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) but without evidence of lamivudine RAMs in baseline proviral DNA population sequencing. Objectives To present 96 week results from ART-PRO. Methods Open-label, single-arm pilot trial. At baseline, all participants switched to dolutegravir plus lamivudine. Participants were excluded if proviral DNA population genotyping detected lamivudine RAMs. To detect resistance minority variants, proviral DNA NGS was retrospectively performed from baseline samples. For this analysis the efficacy endpoint was the proportion of participants with
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkaa479